FDA Peptide Therapy Panel Recommends Six Substances for Compounding Approval

The FDA's Pharmacy Compounding Advisory Committee recommended six of seven peptide substances for inclusion on the Category 1 503A Bulks List in August 2026, a major regulatory step for the peptide therapy industry.

The Category 1 503A Bulks List allows licensed compounding pharmacies to prepare and dispense substances that are not commercially available as FDA-approved drugs. Inclusion on the list gives compounders a clearer legal pathway to produce peptide therapies for patients.

The committee's recommendation covers six of the seven peptides under review. The seventh was not recommended for inclusion. The FDA has not yet issued a final decision on the recommendations, which will go through additional review before taking effect.

Peptide therapies have grown rapidly in popularity over the past several years, driven by interest in treatments for weight management, muscle recovery, anti-aging, and other health goals. The regulatory landscape for these substances has been uncertain, with compounders and patients seeking clearer guidance from the FDA.

The August 2026 recommendation follows years of advocacy from compounding pharmacies and patient groups who argued that many peptide substances are medically necessary and not adequately served by commercially available products.

The FDA's TEMPO pilot, also launched in August 2026, signals the agency's broader interest in integrating new health technologies into existing payment and regulatory frameworks. The peptide compounding decision is part of that larger effort to bring clarity to a fast-moving sector of the health industry.